Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aptevo Therapeutics stock | $42.98

Own Aptevo Therapeutics stock in just a few minutes.

Fact checked

Aptevo Therapeutics Inc is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 80 staff and has a trailing 12-month revenue of around USD$34.4 million.

How to buy shares in Aptevo Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aptevo Therapeutics. Find the stock by name or ticker symbol: APVO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aptevo Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$42.98, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aptevo Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aptevo Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aptevo Therapeutics share price

Use our graph to track the performance of APVO stocks over time.

Aptevo Therapeutics shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$42.98
52-week rangeUSD$2.9442 - USD$60
50-day moving average USD$41.7065
200-day moving average USD$16.0967
Wall St. target priceUSD$65.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.762

Buy Aptevo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aptevo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptevo Therapeutics price performance over time

Historical closes compared with the close of $42.98 from 2020-12-09

1 week (2021-01-11) 18.83%
1 month (2020-12-18) 7.40%
3 months (2020-10-16) 515.76%
6 months (2020-07-17) 448.21%
1 year (2020-01-17) 6,220.59%
2 years (2019-01-18) 2,569.57%
3 years (2018-01-18) 1,186.83%
5 years (2016-01-15) N/A

Aptevo Therapeutics financials

Revenue TTM USD$34.4 million
Gross profit TTM USD$-17,260,000
Return on assets TTM -38.59%
Return on equity TTM -316.98%
Profit margin -54.92%
Book value $0.681
Market capitalisation USD$155 million

TTM: trailing 12 months

Shorting Aptevo Therapeutics shares

There are currently 276,692 Aptevo Therapeutics shares held short by investors – that's known as Aptevo Therapeutics's "short interest". This figure is 71% down from 955,431 last month.

There are a few different ways that this level of interest in shorting Aptevo Therapeutics shares can be evaluated.

Aptevo Therapeutics's "short interest ratio" (SIR)

Aptevo Therapeutics's "short interest ratio" (SIR) is the quantity of Aptevo Therapeutics shares currently shorted divided by the average quantity of Aptevo Therapeutics shares traded daily (recently around 337429.26829268). Aptevo Therapeutics's SIR currently stands at 0.82. In other words for every 100,000 Aptevo Therapeutics shares traded daily on the market, roughly 820 shares are currently held short.

However Aptevo Therapeutics's short interest can also be evaluated against the total number of Aptevo Therapeutics shares, or, against the total number of tradable Aptevo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptevo Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aptevo Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0402% of the tradable shares (for every 100,000 tradable Aptevo Therapeutics shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptevo Therapeutics.

Find out more about how you can short Aptevo Therapeutics stock.

Aptevo Therapeutics share dividends

We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.

Have Aptevo Therapeutics's shares ever split?

Aptevo Therapeutics's shares were split on a 1:14 basis on 27 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.

Aptevo Therapeutics share price volatility

Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $2.9442 up to $60. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 7.5766. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aptevo Therapeutics overview

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site